Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

NCT07370597 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT07370597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07370597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.
Lead sponsor
Jules Bordet Institute
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 31, 2027
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (adenocarcinoma)